CAS Medical Systems

Branford's CAS Medical Systems said it has signed an oximeter distribution agreement with French company Gamida.

Branford manufacturer CAS Medical Systems said regulators have approved the company's request to move its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective today.

Branford medical oximeter maker CAS Medical Systems said its fourth-quarter loss increased to $3.5 million as higher costs took a bite out of flat sales.

Branford medical device manufacturer CAS Medical Systems said the China Food and Drug Administration has approved the sale of its Fore-Sight Cerebral Oximeter.

Branford medical device manufacturer CAS Medical Systems Inc.'s loss deepened in the third quarter to $3.3 million as net sales fell 11 percent due to a slowdown of vital signs monitor sales to the U.S. Veterans Administration, the company reported.

Five months after receiving U.S. Food & Drug Administration approval, Branford's CAS Medical Systems said it has landed the first sale of its new oximeter product.

CAS Medical Systems Inc. widened its second-quarter net loss on flat sales as the Branford biotech launches a new line of vital-signs measurement devices.

CAS Medical Systems announced it has raised $6.5 million through an offering of 5.2 million common shares of its stock.

Branford's CAS Medical Systems Inc. says it will begin marketing as early as July two new patient monitors following clearance from federal drug regulators.

CAS Medical Systems Inc.'s borrowing of an extra $1.5 million requires the Branford biodevice maker pay only the interest for two years, followed by a balloon payment once it matures three years from now, a regulatory filing shows.